The PILLS Act adds two tax-based incentives to spur domestic production of lifesaving medicines: a generic drugs and biosimilars production credit (section 45BB) and a generics/biosimilars investment credit (section 48F). The production credit rewards value added from U.S.-made components of approved generics, biosimilars, and related materials, with a domestic-content bonus and a phased withdrawal beginning in 2031.
The investment credit supports constructing and placing in service qualified facilities building those components, with a 25% credit and a sunset in 2028 for new property. The bill also creates elections to receive credits via elective payment or to transfer credits, and aligns related rules with existing tax-credit structures.
It defines eligible components, sets eligibility criteria, and imposes safeguards tied to FDA-related concerns. The effective date is prospective from enactment.
This is a policy instrument: it uses targeted tax incentives to boost domestic manufacturing capacity for generic drugs and biosimilars, potentially improving supply resilience, job creation, and supply-chain security for lifesaving medicines. The design blends incentive levels, domestic-content requirements, and phased withdrawal to balance near-term production gains with longer-term budget considerations.
At a Glance
What It Does
The bill creates two credits: 45BB production credit for eligible components produced in the U.S. and sold to unrelated parties, and 48F investment credit for qualified investments in domestic facilities that produce eligible components.
Who It Affects
US-based manufacturers of generic drugs and biosimilars, developers building qualified facilities, and taxpayers electing to use elective-payment or transfer provisions.
Why It Matters
It signals a deliberate shift to domestic manufacturing of lifesaving medicines, leveraging tax policy to expand domestic supply, encourage investment, and reduce reliance on foreign sourcing.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The PILLS Act amends the Internal Revenue Code to establish two new credits aimed at expanding domestic production of generic drugs and biosimilars. The 45BB production credit provides a credit against tax for every eligible component produced in the United States and sold to an unrelated purchaser, with the credit calculated as a base percentage of value added in production.
The base rate generally starts at 30% but rises to 35% for the final production of a drug substance, drug product, or biological product, and it can be increased further via a domestic-content bonus tied to the portion of costs attributable to U.S.-produced materials. A phase-out reduces the credit after 2030, declining through 2033 to 0%.
Eligible components include approved generics, licensed biosimilars, and related drug substances and materials, but exclude components produced in facilities with FDA warning letters that lack a close-out letter. Documentation and certification are required for domestic-content calculations, and production must occur within the United States.
The 48F investment credit offers a 25% credit of the qualifying investment in a qualified facility, with defined qualified property and facilities used to produce eligible components, and a sunset on new property placed in service after 12/31/2028. The bill also authorizes elective-payment and credit-transfer mechanics, and requires conforming tax code amendments to integrate these credits with existing credit frameworks.
Together, these provisions aim to spur domestic investment and strengthen the supply chain for lifesaving medicines. The bill authorizes the Secretary to issue regulations and guidance to implement the credits.
The effective date is the date of enactment for both credits, with the investment credit applying to property placed in service after 12/31/2026.
The Five Things You Need to Know
The bill creates Section 45BB for a generic drugs and biosimilars production credit based on value added in the US, with a base rate of 30% (35% for final production).
A domestic-content bonus can raise the credit by up to 0.20 times the domestic-content percentage, subject to documentation and certification rules.
Credits phase out after 2030: 75% in 2031, 50% in 2032, 25% in 2033, then 0%.
Section 48F establishes a 25% investment credit for qualified investments in qualified facilities producing eligible components, with a sunset for property placed in service after 12/31/2028.
The bill includes elective-payment and transfer provisions, and requires regulatory guidance to implement the credits and to coordinate with existing tax-credit rules.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Production credit framework
The GENERIC DRUGS AND BIOSIMILARS PRODUCTION CREDIT (Sec. 45BB) provides an annual credit equal to the value added in the production of eligible components, with the credit earned only when the component is produced in the United States and sold to an unrelated party. The credit is limited to components produced for use in an approved generic drug or licensed biosimilar. The Secretary applies rules similar to Section 45X for trade or business purposes and includes a prohibition on credit for foreign entities of concern. The authorizing framework also delegates regulatory authority to prescribe rules and guidance necessary to carry out the production credit.
Credit amount and computation
The base credit percentage is 30%, rising to 35% for final production of certain items. A domestic-content bonus increases the base credit by a factor dependent on the US-content percentage, with documentation and certification requirements for domestic content. The value added is defined as gross receipts from the sale of the component minus the cost of eligible components purchased from unrelated parties. There is a statutory phase-out schedule beginning after 12/31/2030.
Eligible components and exclusions
Eligible components include approved generic drugs, licensed biosimilars, and related materials used to produce those products. Excluded are components for which production occurs at facilities subject to FDA warning letters without a closing letter. The definitions incorporate existing FDA and biosimilar frameworks to ensure alignment with standard drug-approval and manufacturing criteria.
Phase-out and sunset
For components sold after 12/31/2030, the credit equals the prior amount times a phase-out percentage (75% in 2031, 50% in 2032, 25% in 2033, 0% thereafter). This design creates a finite window for the benefit to drive investment and production in the near term while signaling a transition away from the incentive over time.
Administration and regulation
The bill gives the Secretary authority to prescribe regulations and other guidance necessary to carry out the production credit, including documentation requirements for domestic-content percentages and certifications from unrelated parties. It also modifies existing tax-credit rules to accommodate credit transfers and elective payments.
Elective payment and credit transfers
The bill adds an elective-payment option and allows transfer of credits under Section 6418, enabling taxpayers to elect to receive the credit as a payment (subject to rules) or to transfer the credit to other entities. These mechanisms mirror other credit-transfer provisions, providing flexibility for taxpayers and potential liquidity for qualified projects.
This bill is one of many.
Codify tracks hundreds of bills on Economy across all five countries.
Explore Economy in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- US-based generic drug manufacturers expanding production in the United States, including those with approved generics and licensed biosimilars, who stand to gain a credit tied to value added.
- Biosimilar developers building or expanding U.S. manufacturing capacity, who can qualify for production and investment credits tied to domestic production.
- Investors and taxpayers who place capital into qualified facilities and claim the investment credit, enabling financing for plant construction and equipment.
- Healthcare systems and patients in the United States that could benefit from a more resilient, domestically produced supply of lifesaving medicines through lower or stabilized prices and improved access.
Who Bears the Cost
- Federal government foregoes some tax revenue due to the credits.
- Firms with international or cross-border supply chains that do not qualify for the domestic-content bonus may face higher alternative costs.
- Facilities that cannot meet FDA-related eligibility requirements (e.g., those tied to warning letters) risk exclusion from the credit.
- Compliance costs for documentation and certification of domestic content, as well as ongoing regulatory reporting obligations.
Key Issues
The Core Tension
The core tension is between privileging domestic production and delivering a timely, cost-effective supply of lifesaving medicines. The act pushes capital into U.S. manufacturing with domestic-content rules and a defined sunset, but that design raises questions about long-term supply resilience if incentives vanish and whether the compliance burden will offset near-term gains.
The PILLS Act ties financial incentives to domestic content and to the eligibility of components that are produced in the United States, which could raise production costs for some suppliers and shift supply chain choices toward domestic facilities. The phase-out structure creates a finite window in which incentives are strong, but it also introduces risk that investments initiated near 2030 may not reach full economic viability if the incentive ends abruptly.
By requiring FDA-related compliance rules, certification from unrelated parties, and documentation of domestic content, the bill adds administrative burdens that could dampen early uptake or add to project lead times. The integration with existing credits (e.g., 45X, 48F, and other sections that reference Section 6417) will require careful regulatory alignment to avoid unintended interactions or double counting.
Finally, while the incentives are designed to boost domestic production, the broader market dynamics—like drug approval timelines, regulatory delays, and global supply chain shifts—will continue to influence the ultimate effectiveness of PILLS in achieving durability of lifesaving drug supply.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.